Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer

被引:6
作者
Luo, Xiaoqing [1 ]
Peng, Shunli [1 ]
Ding, Sijie [1 ]
Zeng, Qin [1 ]
Wang, Rong [1 ]
Ma, Yueyun [1 ]
Chen, ShiYu [1 ]
Wang, Yanxia [1 ]
Wang, Wei [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Peoples R China
基金
中国国家自然科学基金;
关键词
SDPR (CAVIN2); KRAS mutation; Lung cancer; PD-L1; Immunotherapy; MUTATION STATUS; ADENOCARCINOMA; EGFR; ASSOCIATION; GENE; EXPRESSION; RESISTANCE; BIOLOGY; TP53;
D O I
10.1186/s12935-021-01756-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Serum Deprivation Protein Response (SDPR) plays an important role in formation of pulmonary alveoli. However, the functions and values of SDPR in lung cancer remain unknown. We explored prognostic value, expression pattern, and biological function of SDPR in non-small cell lung cancer (NSCLC) and KRAS-mutant lung cancers. Methods: SDPR expression was evaluated by quantitative real-time PCR (RT-qPCR), immunohistochemistry (IHC), and Western blot on human NSCLC cells, lung adenocarcinoma tissue array, KRAS-mutant transgenic mice, TCGA and GEO datasets. Prognostic values of SDPR were evaluated by Kaplan-Meier and Cox regression analysis. Bioinformatics implications of SDPR including SDPR-combined transcription factors (TFs) and microRNAs were predicted. In addition, correlations between SDPR, immune checkpoint molecules, and tumor infiltration models were illustrated. Results: SDPR expression was downregulated in tumor cells and tissues. Low SDPR expression was an independent factor that correlated with shorter overall survival of patients both in lung cancer and KRAS-mutant subgroups. Meanwhile, ceRNA network was constructed to clarify the regulatory and biological functions of SDPR. Negative correlations were found between SDPR and immune checkpoint molecules (PD-L1, TNFRSF18, TNFRSF9, and TDO2). Moreover, diversity immune infiltration models were observed in NSCLC with different SDPR expression and copy number variation (CNV) patterns. Conclusions: This study elucidated regulation network of SDPR in KRAS-mutant NSCLC, and it illustrated correlations between low SDPR expression and suppressed immune system, unfolding a prognostic factor and potential target for the treatment of lung cancer, especially for KRAS-mutant NSCLC.
引用
收藏
页数:15
相关论文
共 42 条
[1]   KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition [J].
Adderley, Helen ;
Blackhall, Fiona H. ;
Lindsay, Colin R. .
EBIOMEDICINE, 2019, 41 :711-716
[2]   Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer [J].
Arbour, Kathryn C. ;
Jordan, Emmett ;
Kim, Hyunjae Ryan ;
Dienstag, Jordan ;
Yu, Helena A. ;
Sanchez-Vega, Francisco ;
Lito, Piro ;
Berger, Michael ;
Solit, David B. ;
Hellmann, Matthew ;
Kris, Mark G. ;
Rudin, Charles M. ;
Ni, Ai ;
Arcila, Maria ;
Ladanyi, Marc ;
Riely, Gregory J. .
CLINICAL CANCER RESEARCH, 2018, 24 (02) :334-340
[3]   The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity [J].
Canon, Jude ;
Rex, Karen ;
Saiki, Anne Y. ;
Mohr, Christopher ;
Cooke, Keegan ;
Bagal, Dhanashri ;
Gaida, Kevin ;
Holt, Tyler ;
Knutson, Charles G. ;
Koppada, Neelima ;
Lanman, Brian A. ;
Werner, Jonathan ;
Rapaport, Aaron S. ;
San Miguel, Tisha ;
Ortiz, Roberto ;
Osgood, Tao ;
Sun, Ji-Rong ;
Zhu, Xiaochun ;
McCarter, John D. ;
Volak, Laurie P. ;
Houk, Brett E. ;
Fakih, Marwan G. ;
O'Neil, Bert H. ;
Price, Timothy J. ;
Falchook, Gerald S. ;
Desai, Jayesh ;
Kuo, James ;
Govindan, Ramaswamy ;
Hong, David S. ;
Ouyang, Wenjun ;
Henary, Haby ;
Arvedson, Tara ;
Cee, Victor J. ;
Lipford, J. Russell .
NATURE, 2019, 575 (7781) :217-+
[4]   Drugging the undruggable RAS: Mission Possible? [J].
Cox, Adrienne D. ;
Fesik, Stephen W. ;
Kimmelman, Alec C. ;
Luo, Ji ;
Der, Channing J. .
NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (11) :828-851
[5]   Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers [J].
Dogan, Snjezana ;
Shen, Ronglai ;
Ang, Daphne C. ;
Johnson, Melissa L. ;
D'Angelo, Sandra P. ;
Paik, Paul K. ;
Brzostowski, Edyta B. ;
Riely, Gregory J. ;
Kris, Mark G. ;
Zakowski, Maureen F. ;
Ladanyi, Marc .
CLINICAL CANCER RESEARCH, 2012, 18 (22) :6169-6177
[6]   Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma [J].
Dong, Zhong-Yi ;
Zhong, Wen-Zhao ;
Zhang, Xu-Chao ;
Su, Jian ;
Xie, Zhi ;
Liu, Si-Yang ;
Tu, Hai-Yan ;
Chen, Hua-Jun ;
Sun, Yue-Li ;
Zhou, Qing ;
Yang, Jin-Ji ;
Yang, Xue-Ning ;
Lin, Jia-Xin ;
Yan, Hong-Hong ;
Zhai, Hao-Ran ;
Yan, Li-Xu ;
Liao, Ri-Qiang ;
Wu, Si-Pei ;
Wu, Yi-Long .
CLINICAL CANCER RESEARCH, 2017, 23 (12) :3012-3024
[7]   Targeting ras signalling pathways in cancer therapy [J].
Downward, J .
NATURE REVIEWS CANCER, 2003, 3 (01) :11-22
[8]   Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase [J].
DuPage, Michel ;
Dooley, Alison L. ;
Jacks, Tyler .
NATURE PROTOCOLS, 2009, 4 (07) :1064-1072
[9]   Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience [J].
El Osta, Badi ;
Behera, Madhusmita ;
Kim, Sungjin ;
Berry, Lynne D. ;
Sica, Gabriel ;
Pillai, Rathi N. ;
Owonikoko, Taofeek K. ;
Kris, Mark G. ;
Johnson, Bruce E. ;
Kwiatkowski, David J. ;
Sholl, Lynette M. ;
Aisner, Dara L. ;
Bunn, Paul A. ;
Khuri, Fadlo R. ;
Ramalingam, Suresh S. .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (05) :876-889
[10]   Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients [J].
Falk, Alexander T. ;
Yazbeck, Nathalie ;
Guibert, Nicolas ;
Chamorey, Emmanuel ;
Paquet, Agnes ;
Ribeyre, Lydia ;
Bence, Coraline ;
Zahaf, Katia ;
Leroy, Sylvie ;
Marquette, Charles-Hugo ;
Cohen, Charlotte ;
Mograbi, Baharia ;
Mazieres, Julien ;
Hofman, Veronique ;
Brest, Patrick ;
Hofman, Paul ;
Ilie, Marius .
LUNG CANCER, 2018, 121 :70-75